AMGEN INC — Director's Dealing 2024

May 4, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2024-05-02

Reporting Person: REESE DAVID M (EVP & Chief Technology Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-05-02	Common Stock	F	650	$277.37	Disposed	59326	Direct

Footnotes

F1: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,180 RSUs which will vest on 5/5/2024; 1,363 RSUs which will vest on 4/30/2025; 2,611 RSUs which will vest in installments of 1,286 on 5/2/2025, and 1,325 on 5/2/2026; and 3,814 RSUs which will vest in installments of 1,258 on 5/2/2025, 1,259 on 5/2/2026, and 1,297 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2: These shares include 607 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.